Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fostamatinib→

Fostamatinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
901119-35-5
Molecular formula
C23H26FN6O9P
Molecular weight
580.5 g/mol
Drug class
Spleen tyrosine kinase (SYK) inhibitorimmunomodulatory small molecule
Mechanism of action
Fostamatinib is converted to the active metabolite R406, which inhibits SYK signalling downstream of Fc receptors in macrophages and other immune cells. This reduces antibody-mediated platelet phagocytosis in immune thrombocytopenia.
Indications / reported uses
  • Treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Sources: US DailyMed — TAVALISSE (fostamatinib) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fostamatinib Environmental Risk Assessment (ERA) (the Fostamatinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.